Cargando…

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

OBJECTIVE: To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. METHODS: A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calleja, Miguel Angel, Albanell, Joan, Aranda, Enrique, García-Foncillas, Jesús, Feliu, Anna, Rivera, Fernando, Oyagüez, Itziar, Salinas-Ortega, Laura, Soto Alvarez, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086713/ https://www.ncbi.nlm.nih.gov/pubmed/34810173 http://dx.doi.org/10.1136/ejhpharm-2021-002955

Ejemplares similares

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
por: García-Goñi, Manuel, et al.
Publicado: (2021)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
por: Lobo, Félix, et al.
Publicado: (2021)

Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
por: Mar, Javier, et al.
Publicado: (2022)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain
por: Mareque, María, et al.
Publicado: (2020)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
por: Yang, Jingyan, et al.
Publicado: (2021)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
por: Mareque, Maria, et al.
Publicado: (2021)

Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
por: Estrada, Vicente, et al.
Publicado: (2022)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021)

Use of Floseal(®), a human gelatine-thrombin matrix sealant, in surgery: a systematic review
por: Echave, María, et al.
Publicado: (2014)

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain
por: Rodríguez González-Moro, Jose Miguel, et al.
Publicado: (2015)

Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions
por: Weiser, Sarah, et al.
Publicado: (2022)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Hospitalization budget impact during the COVID-19 pandemic in Spain
por: Carrera-Hueso, F. J., et al.
Publicado: (2021)

The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries
por: Jha, Ashok, et al.
Publicado: (2015)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
por: Gros, Blanca, et al.
Publicado: (2015)

In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma
por: Cardama, Georgina A., et al.
Publicado: (2023)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab
por: Saleem, Tabinda, et al.
Publicado: (2020)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
por: Miguel‐Lillo, B., et al.
Publicado: (2023)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
por: Navarro, F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k6dhsuivs8hiag1tagr71i0q7a